Exemplar

Plus quam XX non-humanae primatu (NHP) autoimmune morbus exempla.

Haec exempla operimentum plures MOA et multa morbo subtypes cum multa species et multiple modos.

Plus quam CC rodent exempla involving 50 genera autoimmune morbo

Customized Pre-orci Strategy secundum medicamento moa et morbus biology

Multiplex deprehendatur tabulatis ad medicamento protegendo et efficaciam iudicium. Fluunt Cytometry platform, pathologia platform, et cellular muneris Platform, etc.

Professional animal Model Services

Inflammatory alvum morbo, NHP Visum

Systemica lupus erythematosus Visum

Atopic Dermatitis Visum

Rheumatoid arthritis, nhp Visum

SJogren scriptor syndrome, NHP Visum

Psoriatic arthritis Visum

Chronicus sinusitis Visum

Xerophthalmia Visum

Uvitis Visum

Eosinophilic Esophagitis Visum

Eosinophilic gastroenteritis Visum

Inflammatory alvum morbo Visum

Idiopathic pulmonalis fibrosis Visum

SJogren scriptor syndrome Visum

Chronic inserere, versus-hospes morbus Visum

Acuti inserere, versus-hospes morbus Visum

IGA Nephropathy Visum

Passio Heymann Nephritis Visum

Neuropathic Dolor Visum

Post-Surgery dolor Visum

Scientia morborum

Morbus mechanism morbo

Characterization

Animal exemplum

Model Analysis

Visum
Periti in pharmaceutics

Documenta Documenta ad Index Design
Studere
Sentiant

Visum
Packaged solution

PK, PD, Tox Research
PK / PD, TK iudicium
integrated pre-orci studium consilium

Visum
Precema problema solvendis

Target Substructio Biomarker Development
unique postulationem novae pharmaca

Visum

High-Tech Enterprise Specialitas in Autoimmune Animal Models

HKEYBIO est contractus Research Organization (CRO) specialiter in preclinical investigationis in agro autoimmune morbo. In comitatu operates parva animal et deprehendatur test facilitas in Suzhou industriae parcum, tum non-humana primate test basi in Guangxi. In condita quadrigis membra se habere extensive preclinical experientia, cum backgrounds in magna internationalis pharmaceutical turmas totaling fere XX annis.

+ annis

Usus in novae medicamento inventa & Development

Autoimmune morbus animal exempla

inter talpas et NHP

Autoimmune-morbus

genera

Prior pre-ind

studiis

Medicinae solutions cum personalized customization

Pre-C.

Investigatio

Client: Dedicavit ad constructionem Bio-muneris materiae fundatur in se-cœnaculo biomacromolucules et related derivationes, tum quod praeparatio eget Nano-carrier systems.

Studium: Study in therapeutica effectus et immune machinationes de congregata Nano-carrier system in lymphoma in mures. Design studio: et clavis puncta huius investigationis consilio sunt primum ad consilio diversis potestate coetibus ad constructionem et proprium de carrier ratio; Secundo determinare leo de medicamento administratione et sanguinem collection. Et experimentum consilium indiget operire deprehendatur therapeutica effectus et immune machinationes, ita etiam momenti ad excogitandum sanguinem collection tempus puncta, deprehendatur Indicatores et numerus animalium includitur in studio.

DISCIPIO

Client Case: Development of a novae antibody medicamento targeting il-XXV ad atopic DERMATITIS (AD).

Client: A pharmaceutical comitatu developing novum antibody targeting in II-XXV via ad curatio ad

Objective: ut constituere efficacia et salus novae anti-II-XXV antibody in preclinical exempla atopic Dermatitis, comparari ad vexillum positivum medicamento imperium.

DISCIPIO

Client: A biotech comitatu dicata ad investigationis et progressionem de caule cellulations, focus in developing orci iudicium medicinae pro tractandi variis morbis.

Studium: Efficacia studio Mesenchymal caule cells ad acuti respiratorii angustia syndrome (ARDS).

Studium Design: Hoc studium requirit specialis operam ad onerariam, repono, gentem, et cellula status prior ad administrationem in investigational uber. Et experimentalem consilio includit humilis, medium, et altum dosis coetibus investigational productum, tum normalis et exemplar potestate coetus. Denique deprehendatur parametri disposito fundatur in characteristic Indicatores de morbo.

DISCIPIO

Client: An egettive PHARMACEUTICAL BIOTECH Focusing in gene Therapy Products, quae developed est AAV productum.

Studium: Efficacia AAV productum est aestimari cum nostris Uveitis mus exemplar.

Design studium: De experimentum ex VI coetus: a normalis coetus, a exemplar imperium coetus, a positivum imperium coetus et humilis, medium et summus dose coetibus in test substantia. Eventus experimentum indicavit quod probatio substantiam demonstrandum bonum salutem profiles, cum medium et summus dose coetus showing superior efficaciam comparari ad positivum imperium coetus. Praeterea erat dose-dependens effectus observari in humili, medium et summus dose coetus.

DISCIPIO

Client: A C. Tempus Biotech focusing in inventa et progressionem de generation adc therapeutics tractare aegros in cancer et autoimmune morbo.

Studium: pluribus ADCs sunt aestimari in preclinical efficacia iudiciis.

Design Study: Alia animal exempla et autoimmune morbo sunt electi fundatur in variis peltas diversis adcs, inter talpas et non-humana primates. Et indicia involved sunt PSORIASIS (PSO), Inflammorisy PROCURBUS Morbi (IBD) Systemica Lupus erythematosus (Su) systemica (SSC). Diversis speciebus, modi, et genera animalis exempla sunt pro diversis indiciis ut mores efficaciam iudiciis. Various potestate medicinae sunt delectus ad diversas exempla, diversis doses sunt disposito ad consequi proposita efficacia iudiciis.

DISCIPIO

Client: A Pharmaceutical Company qui habet developed a nove compositis disposito ad target mitochondrial damnum actis autophagy et possideant Neuro regenerativa proprietatibus. Et clientis tendit ad explorandum potentiale medicinales effectus eorum compositis in an autoimmune-mediata morbo.

Studium: Efficacia studio compositis in convenientem neurologically related autoimmune morbo ..

Design Studere: Intellectus quod Client est scriptor compositis scuta mitochondrial damnum actis autophagy et habet Neuro regenerative proprietatibus. Intellectus de Hostogenesis de multiple lumbos, cum focus in autoimmune-mediated neuroinflamation et demyelination. Electio autem est EAE Model quod optime imitatur key features of plures lumbos, permittens ad taxationem de client scriptor compositis sub pertinet pathologica conditionibus. Dosis et Administration Design: Development of a Dosing Regimen Tailored ad compositum est mechanism de actione, ensuring optimal nuditate ad target TEXTUS ad opportunitate tempus puncta in morbo progressio.

DISCIPIO

Client: A satus-sursum biotech specializing in mRNA medicamento progressionem, cum diversificetur Pipeline in agris infectiosis morbis, tumore immunology et tumore vaccines.

Study: Validation de Antibody Expression pro Various MRNA vaccines.

Design Study: Iniectio diversis generis et concentratione de mRNA vaccines in diversis coetibus non-humana primates, cum sanguine collectione ad diversum puncta; Deprehensio expressio immune cellulis in sanguine ad diversum punctorum usura fluxus Cytometry; Development of Antibody Deprehensio Modi ad Assess Antiby Expression in Serum.

DISCIPIO

Client: dedicavit ad investigationem et progressionem in amet pharmaceutical products per bioactive agentia (Probiotics) in agro Biomedicine et sanitas.

Studium efficaciam studio Gut microbiota supplendo exempla mc903-adductus ad exemplar.

Design Study: Electio autem convenientibus itineribus administrationis, inductione modos, mus modis fundatur in characteres ex exemplaria. Designing vario concentratione de supplendo exempla et eligens idoneam iudicium modos ad determinandum efficaciam.

DISCIPIO

Nove dds Antibodies Cellular

LIQUIDE

Gene

LIQUIDE

ADC Parvus

Moleculars

Vaccinum Microbiota

Nove dds

Client: Dedicavit ad constructionem Bio-muneris materiae fundatur in se-cœnaculo biomacromolucules et related derivationes, tum quod praeparatio eget Nano-carrier systems.

Studium: Study in therapeutica effectus et immune machinationes de congregata Nano-carrier system in lymphoma in mures. Design studio: et clavis puncta huius investigationis consilio sunt primum ad consilio diversis potestate coetibus ad constructionem et proprium de carrier ratio; Secundo determinare leo de medicamento administratione et sanguinem collection. Et experimentum consilium indiget operire deprehendatur therapeutica effectus et immune machinationes, ita etiam momenti ad excogitandum sanguinem collection tempus puncta, deprehendatur Indicatores et numerus animalium includitur in studio.

DISCIPIO
Antibodies

Client Case: Development of a novae antibody medicamento targeting il-XXV ad atopic DERMATITIS (AD).

Client: A pharmaceutical comitatu developing novum antibody targeting in II-XXV via ad curatio ad

Objective: ut constituere efficacia et salus novae anti-II-XXV antibody in preclinical exempla atopic Dermatitis, comparari ad vexillum positivum medicamento imperium.

DISCIPIO
Cellular
LIQUIDE

Client: A biotech comitatu dicata ad investigationis et progressionem de caule cellulations, focus in developing orci iudicium medicinae pro tractandi variis morbis.

Studium: Efficacia studio Mesenchymal caule cells ad acuti respiratorii angustia syndrome (ARDS).

Studium Design: Hoc studium requirit specialis operam ad onerariam, repono, gentem, et cellula status prior ad administrationem in investigational uber. Et experimentalem consilio includit humilis, medium, et altum dosis coetibus investigational productum, tum normalis et exemplar potestate coetus. Denique deprehendatur parametri disposito fundatur in characteristic Indicatores de morbo.

DISCIPIO
Gene
LIQUIDE

Client: An egettive PHARMACEUTICAL BIOTECH Focusing in gene Therapy Products, quae developed est AAV productum.

Studium: Efficacia AAV productum est aestimari cum nostris Uveitis mus exemplar.

Design studium: De experimentum ex VI coetus: a normalis coetus, a exemplar imperium coetus, a positivum imperium coetus et humilis, medium et summus dose coetibus in test substantia. Eventus experimentum indicavit quod probatio substantiam demonstrandum bonum salutem profiles, cum medium et summus dose coetus showing superior efficaciam comparari ad positivum imperium coetus. Praeterea erat dose-dependens effectus observari in humili, medium et summus dose coetus.
DISCIPIO
ADC

Client: A C. Tempus Biotech focusing in inventa et progressionem de generation adc therapeutics tractare aegros in cancer et autoimmune morbo.

Studium: pluribus ADCs sunt aestimari in preclinical efficacia iudiciis.

Design Study: Alia animal exempla et autoimmune morbo sunt electi fundatur in variis peltas diversis adcs, inter talpas et non-humana primates. Et indicia involved sunt PSORIASIS (PSO), Inflammorisy PROCURBUS Morbi (IBD) Systemica Lupus erythematosus (Su) systemica (SSC). Diversis speciebus, modi, et genera animalis exempla sunt pro diversis indiciis ut mores efficaciam iudiciis. Various potestate medicinae sunt delectus ad diversas exempla, diversis doses sunt disposito ad consequi proposita efficacia iudiciis.

DISCIPIO
Parvus
Moleculars

Client: A Pharmaceutical Company qui habet developed a nove compositis disposito ad target mitochondrial damnum actis autophagy et possideant Neuro regenerativa proprietatibus. Et clientis tendit ad explorandum potentiale medicinales effectus eorum compositis in an autoimmune-mediata morbo.

Studium: Efficacia studio compositis in convenientem neurologically related autoimmune morbo ..

Design Studere: Intellectus quod Client est scriptor compositis scuta mitochondrial damnum actis autophagy et habet Neuro regenerative proprietatibus. Intellectus de Hostogenesis de multiple lumbos, cum focus in autoimmune-mediated neuroinflamation et demyelination. Electio autem est EAE Model quod optime imitatur key features of plures lumbos, permittens ad taxationem de client scriptor compositis sub pertinet pathologica conditionibus. Dosis et Administration Design: Development of a Dosing Regimen Tailored ad compositum est mechanism de actione, ensuring optimal nuditate ad target TEXTUS ad opportunitate tempus puncta in morbo progressio.

DISCIPIO
Vaccinum

Client: A satus-sursum biotech specializing in mRNA medicamento progressionem, cum diversificetur Pipeline in agris infectiosis morbis, tumore immunology et tumore vaccines.

Study: Validation de Antibody Expression pro Various MRNA vaccines.

Design Study: Iniectio diversis generis et concentratione de mRNA vaccines in diversis coetibus non-humana primates, cum sanguine collectione ad diversum puncta; Deprehensio expressio immune cellulis in sanguine ad diversum punctorum usura fluxus Cytometry; Development of Antibody Deprehensio Modi ad Assess Antiby Expression in Serum.

DISCIPIO
Microbiota

Client: dedicavit ad investigationem et progressionem in amet pharmaceutical products per bioactive agentia (Probiotics) in agro Biomedicine et sanitas.

Studium efficaciam studio Gut microbiota supplendo exempla mc903-adductus ad exemplar.

Design Study: Electio autem convenientibus itineribus administrationis, inductione modos, mus modis fundatur in characteres ex exemplaria. Designing vario concentratione de supplendo exempla et eligens idoneam iudicium modos ad determinandum efficaciam.

DISCIPIO

Digital showroom

Si vis discere de nostris vestibulum capabilities, vos can click in Avatar in SCENA, aut accipere meum invitatio!

Non solum in elit sed etiam vestra reliable target convalidandum socium

Sanjifenlei_rheumatoid, arthritis, ra-fuben-640-640.webp

CIA Model: A key tool pro analyzing autoimmune responsio

2025-07-17

CIA Model: A key tool pro analyzing autoimmune responsautoimmune morbo, characterised a immune ratio scriptor abnormes impetum in corpore proprium texturis, facti global salutem provocatione.

2025-07-17

Sanjifenlei_psoriasis, Fuben-100-100.WEBP

CIA Model: Innovative Applications of Collagen II adductus

2025-07-24

CIA Model: Innovative Applications of Collagen II inducedin ad dynamic agro vitae scientiae investigationis, in constructione morbus exempla stat quasi in angulo angularis.

2025-07-24

CIA Model: et clavem ad unveiling machinationes of multisystem damnum in Rheumatoid arthritis

2025-07-31

CIA Model: et clavem ad unveiling machinationes of multisystem damnum in rheumatoid arthritisrheumatoid arthritis (r) non modo inordinatio in articulis; Est complexu, inveterata inflammatione conditione cum multo - reaching consequatur.

2025-07-31

Professional animal Model Services

High-Tech Enterprise Specialitas in Autoimmune Animal Models

Medicinae solutions cum personalized customization

Digital showroom

Non solum in elit sed etiam vestra reliable target convalidandum socium

CIA Model: A key tool pro analyzing autoimmune responsio

CIA Model: Innovative Applications of Collagen II adductus

CIA Model: et clavem ad unveiling machinationes of multisystem damnum in Rheumatoid arthritis

Quick Links

Service Catagory

Contact Us